Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of tocilizumab plus DMARDs vs optimized DMARD therapy in early moderate to severe rheumatoid arthritis
2010-019935-37Phase 4Completed
- Sponsor
- Roche
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: DAS28 remission at 12 months. Started Jul 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-019935-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019935-37.